Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: A population-based study

Journal of Oncology Practice

Volumn 5, Issue 4, 2009, Pages 153-158

  Lim, Howard J ^a   Gill, Sharlene ^a   Speers, Caroline ^a   Melosky, Barbara ^a   Barnett, Jeff ^a   Fitzgerald, Catherine ^a   O'Reilly, Susan ^a   Kennecke, Hagen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MITOMYCIN C; OXALIPLATIN; RALTITREXED;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POPULATION RESEARCH; TREATMENT OUTCOME;

EID: 74749087799     PISSN: 15547477     EISSN: None     Source Type: Journal    
DOI: 10.1200/JOP.0942001     Document Type: Article

References (17)

1. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
2. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
3. Jäger E, Heike M, Bernhard H, et al: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial-Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 14:2274-2279, 1996
4. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
5. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
6. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21:129a, 2002 (abstr 512)
7. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
8. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
9. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004
10. Venook A, Niedzwicki D, Hollis D, et al: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 24:148s, 2006 (suppl; abstr 3509)
11. Grothey A, Sargent D, Goldberg, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
12. British Columbia Cancer Agency: Treatment protocols. http://www.bccancer. bc.ca/HPI/default.htm
13. Statistics Canada: 2006 Census. http://www12.statcan.gc.ca/ censusrecensement/index-eng.cfm
14. Canadian Cancer Society: Cancer statistics for 2008. http:// www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics.aspx?sc-lang=en
15. Renouf D, Kennecke H, Gill S: Trends in chemotherapy (CT) utilization for colorectal cancer: A provincial population-based analysis. Clin Colorectal Cancer 7:386-389, 2008
16. O'Connell MJ: Survival following recurrence in patients with adjuvant colon cancer: Findings from the 20,800-patient ACCENT dataset. J Clin Oncol 25:165s, 2007 (suppl; abstr 4009)
17. Saltz L, Clarke S, Diaz-Rubio E, et al: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 25: 170s, 2007 (suppl; abstr 4028)